Hepatopulmonary Syndrome
Also known as: HPS
Hepatopulmonary syndrome (HPS) is the triad of liver disease (usually cirrhosis with portal hypertension), arterial hypoxaemia and intrapulmonary vascular dilatation.
Occurs in 5 to 32% of patients with cirrhosis and portal hypertension (also portal vein thrombosis, Budd Chiari).
Pathogenesis: increased pulmonary nitric oxide, endothelin B receptor activity, angiogenesis and monocyte accumulation leading to capillary dilatation (up to 60 µm), ventilation perfusion mismatch, diffusion limitation.
Severity by PaO2: mild 80 mmHg or more, moderate 60 to 80, severe 50 to 60, very severe under 50 mmHg (breathing room air, with A a gradient 15 mmHg or more, or 20 in over 64 years).
Predicts poor survival (median 24 months untreated vs 87 months without HPS); resolves in majority after liver transplantation.













